Aptose Biosciences Inc. (APTO)
Largest Insider Buys in Sector
APTO Stock Price History Chart
APTO Stock Performance
About Aptose Biosciences Inc.
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and HM43239 that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops luxeptinib, which is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin's lymphomas, as well as AML and HR MDS; and APL-581, a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor program. It has agreements with CrystalGenomics, Inc. and OHM Oncology. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.
Insider Activity of Aptose Biosciences Inc.
Over the last 12 months, insiders at Aptose Biosciences Inc. have bought $20,000 and sold $0 worth of Aptose Biosciences Inc. stock.
On average, over the past 5 years, insiders at Aptose Biosciences Inc. have bought $165,712 and sold $1.43M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Rice William G. (Chair, President & CEO) — $20,000.
The last purchase of 100,000 shares for transaction amount of $20,000 was made by Rice William G. (Chair, President & CEO) on 2024‑11‑25.
List of Insider Buy and Sell Transactions, Aptose Biosciences Inc.
| 2024-11-25 | Chair, President & CEO | 100,000 0.5592% | $0.20 | $20,000 | +7.87% | |||
| 2023-09-22 | director | 17,000 0.2389% | $3.14 | $53,380 | -46.38% | |||
| 2022-06-06 | Chair, President & CEO | 10,000 0.0109% | $0.97 | $9,681 | -32.29% | |||
| 2021-12-20 | director | 10,000 0.0117% | $1.45 | $14,490 | -38.49% | |||
| 2021-12-16 | director | 100,000 0.1055% | $1.38 | $137,900 | -41.50% | |||
| 2021-12-16 | Chair, President & CEO | 13,183 0.0153% | $1.52 | $20,038 | -41.50% | |||
| 2021-12-15 | director | 270,000 0.2989% | $1.17 | $316,340 | -27.73% | |||
| 2021-12-15 | Chair, President & CEO | 17,822 0.0189% | $1.12 | $19,961 | -27.73% | |||
| 2021-11-26 | Chair, President & CEO | 8,643 0.0098% | $2.31 | $19,965 | -57.89% | |||
| 2021-11-19 | Sr. VP, Chief Medical Officer | 10,000 0.0115% | $2.56 | $25,600 | -59.76% | |||
| 2021-08-05 | Sale | 10 percent owner | 60,000 0.0677% | $2.62 | $157,200 | -51.72% | ||
| 2021-08-03 | 10 percent owner | 57,199 0.0647% | $2.65 | $151,406 | -51.52% | |||
| 2021-07-02 | Chair, President & CEO | 6,081 0.0067% | $3.29 | $19,998 | -57.78% | |||
| 2021-06-22 | Sale | director | 9,600 0.0106% | $3.24 | $31,104 | -55.59% | ||
| 2021-06-21 | Sale | director | 15,400 0.0174% | $3.35 | $51,590 | -55.56% | ||
| 2020-12-22 | Sale | director | 20,000 0.0234% | $4.06 | $81,200 | -20.52% | ||
| 2020-07-10 | Sale | Chair, President & CEO | 168,891 0.1977% | $6.05 | $1.02M | -16.11% | ||
| 2020-07-10 | Sale | Executive VP & CFO | 126,668 0.1483% | $6.05 | $766,341 | -16.11% | ||
| 2020-07-10 | Sale | Senior VP, Chief Bus. Officer | 62,835 0.0735% | $6.05 | $380,152 | -16.11% | ||
| 2020-07-02 | Sale | Senior VP, Chief Bus. Officer | 20,946 0.0238% | $6.34 | $132,793 | -22.08% |
Insider Historical Profitability
| Rice William G. | Chair, President & CEO | 613252 1.019% | $0.20 | 10 | 1 | +2.47% |
| Wilson Donald R. Jr. | 10 percent owner | 8888275 14.7692% | $0.20 | 1 | 1 | <0.0001% |
| PLATZER ERICH | director | 505000 0.8391% | $0.20 | 3 | 1 | <0.0001% |
| Chow Gregory K. | Executive VP & CFO | 232846 0.3869% | $0.20 | 2 | 1 | +46.02% |
| Marango Jotin | Senior VP, Chief Bus. Officer | 116219 0.1931% | $0.20 | 0 | 2 | |
| BURGER DENIS R | director | 31671 0.0526% | $0.20 | 1 | 0 | <0.0001% |
| Seizinger Bernd R. | director | 17000 0.0282% | $0.20 | 1 | 0 | |
| Whitehead Warren | director | 15000 0.0249% | $0.20 | 0 | 5 | |
| Bejar Rafael | Sr. VP, Chief Medical Officer | 10000 0.0166% | $0.20 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
| Annandale Capital | $44,000.00 | 0.15 | 26,666 | -64.29% | -$79,201.98 | 0.01 | |
| Caldwell Sutter Capital Inc | $153.00 | <0.01 | 92 | 0% | +$0 | <0.0001 |